1) A Phase 1, Open Label, Dose Escalation, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR-103 in Patients with Relapsed Advanced Malignancies (BHARAT-1)
1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors2) A Highly Differentiated A2AR Inhibitor
Aurigene will be participating at the annual American Society of Hematology (ASH) Conference scheduled to be held in Atlanta, Georgia from December 9-12. More information about the conference can be
Aurigene will be participating at the annual Society for Immunotherapy of Cancer (SITC) International Conference scheduled to be held at the Gaylord National Hotel & Convention Center in National Harbor, Maryland
Aurigene will be participating at the annual AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics scheduled to be held at Philadelphia, PA on October 26-30, 2017. More information about the conference
Aurigene will be attending the New York Bio’s Annual Meeting, scheduled to be held on May 10-11, 2017 at New York City. For more details about the event, please click here.
Aurigene will be attending 2017 MassBio Annual Meeting, scheduled to be held on March 30-31, 2017 at Boston, Massachusetts. For more details about the conference, please click here
Aurigene will be attending 2017 American Academy of Dermatology Annual Meeting, scheduled to be held on March 03-07, 2017 at Orlando, Florida. For more details about the conference, please click
Advances in New Drug Discovery & Development Feb 2-4, 2017, Ahmedabad, India Scientists and R & D professionals from across the globe will be at arms reach when they gather
